ASX Announcement

ASX:

CUV

Nasdaq International Designation: CLVLY

XETRA-DAX:

UR9

CLINUVEL STRATEGIC UPDATE

Dual strategy for melanocortins

____________________________________________________________________________________________________________________________________

Melbourne, Australia, 29 October 2020

CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An extensive version (31 slide illustrations) and executive summary (13 slide illustrations) have both been lodged with the ASX.

CLINUVEL is focussing on the commercialisation of the medicinal product SCENESSE® (afamelanotide controlled- release) for the treatment of erythropoietic protoporphyria (EPP) in the European Union, United States and - since 26 October - Australia.

The Update reveals CLINUVEL's strategic intentions are described as dual: ongoing work to scientifically translate melanocortins as prescription medicines for further life-threatening disorders as well as making the technology available for healthcare solutions as non-prescription products. The focus of the latter product category is to provide DNA protection and repair of the skin in individuals at highest risk of solar skin damage from UV exposure.

- End -

Media enquiries

Monsoon Communications

Mr Rudi Michelson, 61 411 402 737, rudim@monsoon.com.au

Notes to editors:

CLINUVEL's Strategic Update has been issued to the Australian Securities Exchange and is available on CLINUVEL's website www.clinuvel.com.

1 SCENESSE® (afamelanotide 16mg) is approved in the European Union and Australia as an orphan medicinal product and the world's first systemic photoprotective pharmaceutical for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase "pain- free" light exposure in adult EPP patients with a history of phototoxicity. Information on the product can be found on CLINUVEL's website at www.clinuvel.com.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014, the US Food and Drug Administration in 2019 and the Australian Therapeutic Goods Administration in 2020 for the prevention of phototoxicity (anaphylactoid

reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA. For more information please go to http://www.clinuvel.com.

SCENESSE® and PRÉNUMBRA® are two of several registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor enquiries https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, the COVID-19 pandemic affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2020 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com

Level 11

T +61 3 9660 4900

535 Bourke Street

F +61 3 9660 4999

Melbourne

Victoria, Australia, 3000

Strategic Update

Targeted Technology Translation

CLINUVEL Group

29 October 2020

ASX:

CUV

Level 1 ADR (Nasdaq International Designation):

CLVLY

XETRA‐DAX:

UR9

www.clinuvel.com

Today we share CLINUVEL's strategy, its planning and execution which started in November 2005 and which concluded in June 2006.

In order to communicate to all readers coming from varying backgrounds, the language and definitions used in these illustrations are balanced with a mix of technical and simple expressions so that a non‐technical audience is able to understand the concepts and thought processes underlying the successfully executed strategy, while an executive summary is also announced and published on CLINUVEL's website (clinuvel.com) provided for faster reading.

While any navigating crew needs to adjust continuously to unexpected events, adverse conditions, and unforeseen hazards, nearly all objectives set in 2006 have been realised.

The time it took to overturn regulatory objections, scepticism and adversities has been long and has required much patience and incalculable persistence from the same CLINUVEL team which had started the journey exactly 15 years ago.

Now today, the next chapter in the use of melanocortins is unveiled as data, scientific progress, safety and an environment of acceptance of the technology has been established. The strategy is unfolding as had been designed and desired a long time ago with some variations allowing for changes to the business plan when needed; flexibility is imperative when executing complexities.

At these uncertain times of global viral threat, one is required to look ahead and imagine how the world will look, a new world order, new internatonal economic relationships, a digital era and a high level of individualism, requiring one to take responsibility for one's own life.

All of the Group's staff, employees and Board share one common trait:

At CLINUVEL, we realise each day that it is a privilege to work for our common causes and to build a company from its ashes to its current remarkable success, while staying humble to the fact that success can vanish overnight when one becomes complacent. Too big to fail does not exist in our minds nor to small to succeed where others ceased, we manage uncertainty and build in contingency scenarios where we can.

Today, will focus on the expansion of the Pharmaceutical Division as well as the revelation of the Healthcare

www.clinuvel.com

Solutions Division, making CLINUVEL a unique hybrid among its peers, but with good reason.

Whereas it has taken decades of innovation, research and development to bring to market(s) a truly unique pharmaceutical product ‐ SCENESSE® (afamelanotide 16mg) ‐ the derivatives and further application should be finding its way to the markets in significantly less time; and that anticipation is owing to the fact that knowledge, IP, data and scientific observations are all transportable to CLINUVEL's downstream applications, products and target markets.

Whereas in pharmaceuticals and medicine one frequently speaks of translational science, when using one technology for wider medicinal use, in contrast it is rare to find highly specialised medical technology which can be rendered into a non‐medical application for universal use. At CLINUVEL we had identified this differential pathway in 2006, but were required - for the protection of patients and our own - to prove safety of the melanocortin beyond any reasonable doubt.

The Group has have arrived at a point where the scientific breakthrough of melanocortins will be made available for wider societal utility, benefit for all at risk, all of us who self‐identify a need.

With considerable humility, the CLINUVEL staff summarises the execution of this strategy as the completion of a trilogy, the third chapter of a planned CLINUVEL journey, Targeted Technology Translation.

The reader will come away with answers to the questions, WHAT - WHY - HOW - WHERE - and WHEN.

www.clinuvel.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 29 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2020 01:39:08 UTC